Navigation Links
Navigenics'(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments
Date:4/8/2008

REDWOOD SHORES, Calif., April 8, 2008 /PRNewswire/ -- Navigenics, a genetic health services company, today announced a new study of genetic predisposition analysis. The Mayo Clinic study will examine how patients understand and use information provided by a Navigenics genetic risk assessment. The research also addresses physicians' understanding of genetic assessments and the impact of such information on preventive health decision making. Titled "A Proof of Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment," the study begins this month and runs through September 2009. The study is funded jointly by Navigenics and Mayo Clinic.

"In this emerging field it is absolutely critical that the entire industry remain rooted in high-quality science and research - this is exactly what we do and what our customers, collaborators and advisors expect from Navigenics," said Mari Baker, president and CEO of Navigenics. "We believe this research collaboration with a leading medical institution like Mayo Clinic will help the entire industry evolve responsibly, provide the necessary tools to educate clinicians, and ultimately improve people's lives."

The Navigenics(TM) Health Compass is a new genetic risk assessment service that combines an advanced genome scan with the latest discoveries in genetic medicine and personalized genetic counseling. It gives individuals information on their genetic predisposition to developing a broad menu of common conditions, so that, with their physicians, they can seek earlier diagnosis, delay the onset or prevent the conditions altogether. The service calculates genetic predisposition based on genome-wide association studies that combine a variety of epidemiological variables. Navigenics scours the more than 4,000 published studies correlating genes to medical conditions and other common human traits to include only those which present high-quality and reliable results. The Navigenics Health Compass is the only personal genetic risk assessment to provide on-staff Certified Genetic Counselors to help people understand their individual results.

"The science that links genes with many common inherited diseases is well- established and growing," said Navigenics co-founder and clinical advisory board chair David Agus, M.D. "Now we need to better understand how individuals use this information. Navigenics hopes to learn more about patients' hopes and expectations regarding genetic risk assessment. Our goal is to leverage the wealth of information that genetics can provide to better motivate patients to take action that will improve their health. Our research collaboration with the Mayo Clinic helps us get there."

About Navigenics

Navigenics, Inc. is a privately held company based in Redwood Shores, Calif. The company was founded by David Agus, M.D. and Dietrich Stephan, Ph.D., with the goal of improving health outcomes in individuals across the population. Navigenics educates and empowers customers with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics' lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures. More information is available at http://www.navigenics.com.

FOR MORE INFORMATION:

Hal Mackins

Feinstein Kean Healthcare

Hal.mackins@fkhealth.com

(415) 677-2747

(415) 994-0040 - mobile

Brenna Sweeney

Navigenics

bsweeney@navigenics.com

(206) 999-4796


'/>"/>
SOURCE Navigenics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
2. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
3. Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
4. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
5. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
6. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
7. Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)
8. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
Breaking Medicine News(10 mins):